Trofinetide
High EvidenceA twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization.
What It Is
Trofinetide (development code NNZ-2566; Acadia Pharmaceuticals, brand name Daybue) is a synthetic analog of glycine-proline-glutamate (GPE, also called glypromate), the naturally occurring N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). It is the first drug ever approved for Rett syndrome, a rare and severe neurodevelopmental disorder caused almost entirely by loss-of-function mutations in the X-linked gene MECP2. Rett syndrome affects predominantly girls (roughly 1 in 10,000-15,000 female births); after a period of apparently normal early development, children undergo a regression that costs them purposeful hand use and spoken language and leaves them with stereotypic hand movements, gait and breathing abnormalities, seizures and profound communication impairment. Because MECP2 sits at the top of a broad gene-regulation network, its loss disturbs synapse formation and maturation, glial function and neuroinflammatory tone rather than a single pathway - which is why a small, pleiotropic peptide is an attractive therapeutic strategy. Native GPE is cleaved from IGF-1 and has neurotrophic and neuroprotective activity, but it is metabolically unstable; trofinetide is engineered (a 2-methylproline substitution) to resist breakdown and achieve drug-like exposure. It is given as a weight-based oral solution twice daily. In the pivotal 12-week placebo-controlled Phase 3 LAVENDER trial of 187 girls and young women aged 5-20, trofinetide produced statistically significant improvement over placebo on both co-primary endpoints - the caregiver-rated Rett Syndrome Behaviour Questionnaire (RSBQ) and the clinician-rated Clinical Global Impression-Improvement (CGI-I) - leading to FDA approval on March 10, 2023 for patients 2 years and older. Open-label extension studies (LILAC, LILAC-2) and the real-world LOTUS study support durable benefit, and gastrointestinal tolerability (diarrhea and vomiting) is the main practical limitation. Trofinetide is a physician-prescribed medicine, not a self-sourced research chemical. In 2026 the program advanced on two fronts: the FDA approved Daybue STIX, a dye- and preservative-free powder formulation that became broadly available in April 2026, and in June 2026 the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion after re-examination, recommending marketing authorization in Europe.
Regulatory Status
Trofinetide (Daybue, Acadia Pharmaceuticals) received FDA approval on March 10, 2023 as the first and only treatment for Rett syndrome, indicated for adults and pediatric patients 2 years of age and older. In December 2025 the FDA approved Daybue STIX, a dye- and preservative-free powder formulation, which became broadly available to U.S. families in April 2026. In June 2026 the EMA's CHMP adopted a positive opinion (following re-examination) recommending marketing authorization in the EU. It is a specialist-prescribed oral medicine; any vendor selling 'trofinetide' or 'NNZ-2566' powder for self-use is illegitimate.
Effective: July 2026
View FDA SourceWhy Researchers Study It
Trofinetide is a landmark case in peptide therapeutics for two reasons. First, it is the first medicine of any kind approved for Rett syndrome - a disorder that, because it stems from loss of a master gene-regulator (MECP2), had long been considered too pleiotropic to drug. Rather than trying to replace MECP2 or fix a single broken pathway, trofinetide takes a 'restore the tone' approach: it mimics a tiny endogenous fragment of IGF-1 (the tripeptide GPE) that has broad neurotrophic and anti-inflammatory activity, nudging many downstream processes - synaptic maturation, dendritic health, microglial and astrocytic activation, and inflammatory-cytokine output - back toward normal at once. Second, it is a clean example of medicinal-chemistry stabilization of a fragile natural peptide: native GPE is metabolically short-lived, and a single methyl-proline substitution converts it into an orally dosable drug. For peptide scientists, trofinetide is a template for treating neurodevelopmental and neurodegenerative conditions with small, multi-target neuropeptide analogs, and it has renewed interest in the IGF-1/GPE axis (which overlaps with other neurotrophic strategies such as davunetide, cerebrolysin and dihexa) as a druggable target.
Proposed Mechanisms
- Synthetic analog of glycine-proline-glutamate (GPE / glypromate), the N-terminal tripeptide naturally cleaved from IGF-1, stabilized by a 2-methylproline substitution for oral, drug-like exposure
- Thought to increase the availability and activity of IGF-1-pathway signaling, supporting neuronal survival, dendritic and synaptic maturation
- Reduces production of pro-inflammatory cytokines and dampens neuroinflammation in the central nervous system
- Normalizes the overactivation of microglia and astrocytes (glial cells) implicated in Rett syndrome pathology
- Promotes synaptic and dendritic health downstream of MECP2 loss rather than correcting the underlying genetic mutation
- Acts as a small, pleiotropic (multi-target) neurotrophic peptide - restoring signaling tone across several pathways instead of blocking a single receptor
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| RCT (human, Phase 3 - pivotal) | Rett syndrome - LAVENDER: 187 girls/young women aged 5-20, oral trofinetide vs placebo over 12 weeks | Statistically significant improvement over placebo on both co-primary endpoints - the caregiver-rated Rett Syndrome Behaviour Questionnaire (RSBQ) and clinician-rated Clinical Global Impression-Improvement (CGI-I); basis for FDA approval | Source |
| Regulatory milestone | Rett syndrome (Acadia Pharmaceuticals) | FDA approval March 10, 2023 - first and only treatment for Rett syndrome, for adults and children 2+; dye/preservative-free Daybue STIX approved Dec 2025 (broadly available April 2026); EMA CHMP positive opinion June 2026 | Source |
| Real-world / long-term evidence | Rett syndrome - LOTUS real-world study, 277 people living with Rett syndrome, up to 12 months of treatment | Caregiver-reported improvements across behavior, nonverbal communication, alertness and social interaction; diarrhea was the most common GI adverse event (reported in ~23-50% early); published in Developmental Medicine & Child Neurology | Source |
| Real-world treatment landscape (2026) | Rett syndrome - U.S. cohort comparing individuals treated vs untreated with trofinetide | Characterized demographic and clinical profiles of trofinetide-treated versus untreated patients in routine practice, informing real-world uptake and management; published 2026 | Source |
Commonly Discussed Benefits
Researching Trofinetide? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Approved specifically for Rett syndrome; it treats neurobehavioral symptoms and does not correct the underlying MECP2 mutation or cure the disorder - it is disease-managing, not disease-reversing
- Gastrointestinal side effects are common and are the main practical limitation: diarrhea (very common, reported in a large share of patients) and vomiting can cause dehydration and weight loss and sometimes lead to dose reduction or discontinuation; caregivers are counseled on diarrhea management and stopping certain anti-diarrheal-conflicting medicines
- A physician-prescribed oral medicine given under specialist (neurology/genetics) supervision as a weight-based solution twice daily - not a self-administered 'research peptide.' Any vendor selling 'trofinetide' or 'NNZ-2566' powder is illegitimate and unsafe
- Dosing is by body weight and requires the correct volume twice daily; the newer Daybue STIX powder is dye- and preservative-free but is still a prescription formulation prepared per label instructions
- Approved based on 12-week neurobehavioral endpoints (RSBQ and CGI-I); longer-term effects on core function, seizures and disease trajectory continue to be characterized in extension (LILAC/LILAC-2) and real-world (LOTUS) studies
- Not medical advice. Eligibility, dosing, GI monitoring and management are individualized decisions made by a qualified clinician
Comparisons
See how Trofinetide compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Trofinetide - Wikipedia PubMed
- [2] Development of trofinetide for the treatment of Rett syndrome: from bench to bedside - PMC PubMed
- [3] Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 LAVENDER Trial of Trofinetide in Rett Syndrome PubMed
- [4] Real-World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability of DAYBUE (trofinetide) Published in Developmental Medicine & Child Neurology - Acadia PubMed
- [5] Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States - JHEOR (2026) PubMed
Keep researching in the app
- Log Trofinetide to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Dihexa
Low EvidenceA hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation.
Cerebrolysin
Medium EvidenceA porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions.
Davunetide
Low EvidenceAn eight-amino-acid ADNP-derived peptide studied for microtubule stabilization, tau-related neuroprotection, and rare ADNP syndrome.
Palopegteriparatide
High EvidencePalopegteriparatide (Yorvipath, developed as TransCon PTH) is Ascendis Pharma's once-daily prodrug of parathyroid hormone (1-34). An inert methoxy-PEG carrier is attached to PTH(1-34) through a TransCon linker that auto-cleaves at physiologic pH and temperature, releasing unmodified native-sequence PTH slowly enough to hold hormone levels inside the physiologic range for a full 24 hours. It is the first therapy approved as a true hormone replacement for chronic hypoparathyroidism rather than as an add-on to calcium and active vitamin D: in the Phase 3 PaTHway trial 78.7% of treated adults met a composite endpoint of normal serum calcium plus independence from conventional therapy at week 26, versus 4.8% on placebo. The FDA approved Yorvipath on August 9, 2024.